FDA Approves First mRNA Seasonal Flu Vaccine for Adults 50 and Older

The U.S. Food and Drug Administration has approved the first mRNA-based seasonal flu vaccine for adults aged 50 and older, marking a significant advancement in vaccine technology. This approval, granted on August 5, 2026, could accelerate the development of future mRNA-based therapies.